The ustekinumab (Stelara; Janssen Biotech) biosimilar DMB-3115 (Imuldosa; Accord BioPharma) demonstrated clinical efficacy and safety comparable to the reference product through 52 weeks in a recent ...

Though earlier clinical trials have suggested ustekinumab (Stelara®) may be an effective therapy for the treatment of systemic lupus erythematosus, the latest research findings call the drug’s ...

A review of literature published over the last 5 years on ustekinumab in Crohn disease (CD) summarized 42 clinical studies on the efficacy and safety of ustekinumab products, including biosimilars, ...

In an extension of a phase II clinical drug trial, ustekinumab (Stelara®) was found to be a safe and effective treatment for lupus over two years of use. Researchers assessed multiple measures of ...

Learn everything you need to know about Ustekinumab-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings ...

Please provide your email address to receive an email when new articles are posted on . Higher ustekinumab trough concentration levels correlated with increased rates of endoscopic remission among ...

Risankizumab (Skyrizi) resulted in more clinical remissions compared with ustekinumab (Stelara) in adults with moderate to severe Crohn's disease who had failed at least one previous tumor necrosis ...

The US Food and Drug Administration (FDA) has approved ustekinumab-auub (Wezlana) as a biosimilar to ustekinumab (Stelara) for the treatment of multiple inflammatory conditions. This is the first ...

The US Food and Drug Administration has approved the dual interleukin (IL)-12 and IL-23 inhibitor ustekinumab (Stelara) for the treatment of juvenile psoriatic arthritis (jPsA) in patients aged 6 ...